For instance, there is evidence that SIRT3 is a negative regulator of cardiac hypertrophy via the activation of FOXO3a-dependent anti-oxidants and by impeding mtROS-mediated Ras activation and downstream MAPK/ERK and PI3K/Akt signaling [108,109]. The gene discussed is SIRT3; the disease is cardiac hypertrophy.